Literature DB >> 18492460

Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy.

Zeeshan Butt1, Sarah K Rosenbloom, Amy P Abernethy, Jennifer L Beaumont, Diane Paul, Debra Hampton, Paul B Jacobsen, Karen L Syrjala, Jamie H Von Roenn, David Cella.   

Abstract

Cancer fatigue has been defined and described as an important problem. However, few studies have assessed the relative importance of fatigue compared with other patient symptoms and concerns. To explore this issue, the authors surveyed 534 patients and 91 physician experts from 5 NCCN member institutions and community support agencies. Specifically, they asked patients with advanced bladder, brain, breast, colorectal, head and neck, hepatobiliary/pancreatic, kidney, lung, ovarian, or prostate cancer or lymphoma about their "most important symptoms or concerns to monitor." Across the entire sample, and individually for patients with 9 cancer types, fatigue emerged as the top-ranked symptom. Fatigue was also ranked most important among patients with 10 of 11 cancer types when asked to rank lists of common concerns. Patient fatigue ratings were most strongly associated with malaise (r = 0.50) and difficulties with activities of daily living, pain, and quality of life. Expert ratings of how much fatigue is attributable to disease versus treatment mostly suggested that both play an important role, with disease-related factors predominant in hepatobiliary and lung cancer, and treatment-related factors playing a stronger role in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18492460      PMCID: PMC5089809          DOI: 10.6004/jnccn.2008.0036

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  10 in total

1.  Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition.

Authors:  N J Vogelzang; W Breitbart; D Cella; G A Curt; J E Groopman; S J Horning; L M Itri; D H Johnson; S L Scherr; R K Portenoy
Journal:  Semin Hematol       Date:  1997-07       Impact factor: 3.851

Review 2.  Control of common, non-pain cancer symptoms.

Authors:  Jamie H Von Roenn; Judith A Paice
Journal:  Semin Oncol       Date:  2005-04       Impact factor: 4.929

Review 3.  Fatigue and the cancer experience: the state of the knowledge.

Authors:  M L Winningham; L M Nail; M B Burke; L Brophy; B Cimprich; L S Jones; S Pickard-Holley; V Rhodes; B St Pierre; S Beck
Journal:  Oncol Nurs Forum       Date:  1994 Jan-Feb       Impact factor: 2.172

4.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.

Authors:  M M Oken; R H Creech; D C Tormey; J Horton; T E Davis; E T McFadden; P P Carbone
Journal:  Am J Clin Oncol       Date:  1982-12       Impact factor: 2.339

5.  The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

Authors:  D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon
Journal:  J Clin Oncol       Date:  1993-03       Impact factor: 44.544

Review 6.  Cancer-related fatigue: A critical appraisal.

Authors:  G Prue; J Rankin; J Allen; J Gracey; F Cramp
Journal:  Eur J Cancer       Date:  2006-02-07       Impact factor: 9.162

7.  What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN).

Authors:  David Cella; Diane Paul; Susan Yount; Rodger Winn; Chih-Hung Chang; Donald Banik; Jane Weeks
Journal:  Cancer Invest       Date:  2003       Impact factor: 2.176

8.  The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals.

Authors:  D Irvine; L Vincent; J E Graydon; N Bubela; L Thompson
Journal:  Cancer Nurs       Date:  1994-10       Impact factor: 2.592

9.  Longitudinal screening and management of fatigue, pain, and emotional distress associated with cancer therapy.

Authors:  Zeeshan Butt; Lynne I Wagner; Jennifer L Beaumont; Judith A Paice; Joshua L Straus; Amy H Peterman; George Carro; Jamie H Von Roenn; Dan Shevrin; David Cella
Journal:  Support Care Cancer       Date:  2007-07-03       Impact factor: 3.603

Review 10.  Fatigue and cancer: causes, prevalence and treatment approaches.

Authors:  L I Wagner; D Cella
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  10 in total
  69 in total

1.  The development and testing of an instrument for perceived self-efficacy for fatigue self-management.

Authors:  Amy J Hoffman; Alexander von Eye; Audrey G Gift; Barbara A Given; Charles W Given; Marilyn Rothert
Journal:  Cancer Nurs       Date:  2011 May-Jun       Impact factor: 2.592

Review 2.  Health-related quality of life in ovarian cancer patients and its impact on clinical management.

Authors:  Dana M Chase; Lari Wenzel
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

3.  Metastatic breast cancer patients' expectations and priorities for symptom improvement.

Authors:  Danielle B Tometich; Catherine E Mosher; Adam T Hirsh; Kevin L Rand; Shelley A Johns; Marianne S Matthias; Samantha D Outcalt; Bryan P Schneider; Lida Mina; Anna Maria V Storniolo; Erin V Newton; Kathy D Miller
Journal:  Support Care Cancer       Date:  2018-05-07       Impact factor: 3.603

4.  Effect of Baduanjin Qigong Exercise on Cancer-Related Fatigue in Patients with Colorectal Cancer Undergoing Chemotherapy: A Randomized Controlled Trial.

Authors:  Yun Lu; Hui-Qin Qu; Feng-Ying Chen; Xiao-Ting Li; Lan Cai; Shan Chen; Yuan-Yuan Sun
Journal:  Oncol Res Treat       Date:  2019-07-02       Impact factor: 2.825

5.  Validation of the Hindi version of the Multidimensional Fatigue Inventory-20 (MFI-20) in Indian cancer patients.

Authors:  Priyanka Chandel; Armiya Sultan; Khan Abraruzzaman Khan; Vivek Choudhary; Arti Parganiha
Journal:  Support Care Cancer       Date:  2015-03-06       Impact factor: 3.603

6.  Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

Authors:  Richard T Penson; Helen Q Huang; Lari B Wenzel; Bradley J Monk; Sharon Stockman; Harry J Long; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J A Reid; Mario M Leitao; Michael Method; Helen Michael; Krishnansu S Tewari
Journal:  Lancet Oncol       Date:  2015-01-29       Impact factor: 41.316

7.  Measurement of fatigue in cancer, stroke, and HIV using the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scale.

Authors:  Zeeshan Butt; Jin-Shei Lai; Deepa Rao; Allen W Heinemann; Alex Bill; David Cella
Journal:  J Psychosom Res       Date:  2012-11-15       Impact factor: 3.006

8.  Recommendations for high-priority research on cancer-related fatigue in children and adults.

Authors:  Andrea M Barsevick; Michael R Irwin; Pamela Hinds; Andrew Miller; Ann Berger; Paul Jacobsen; Sonia Ancoli-Israel; Bryce B Reeve; Karen Mustian; Ann O'Mara; Jin-Shei Lai; Michael Fisch; David Cella
Journal:  J Natl Cancer Inst       Date:  2013-09-18       Impact factor: 13.506

9.  Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae.

Authors:  Catherine E Mosher; Courtney Johnson; Maura Dickler; Larry Norton; Mary Jane Massie; Katherine DuHamel
Journal:  Breast J       Date:  2013-03-26       Impact factor: 2.431

10.  A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

Authors:  Deepa Rao; Zeeshan Butt; Sarah Rosenbloom; Don Robinson; Jamie Von Roenn; Timothy M Kuzel; David Cella
Journal:  J Pain Symptom Manage       Date:  2009-04-08       Impact factor: 3.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.